Ceftriaxone + Sulbactam is a fixed-dose combination injectable antibiotic. Ceftriaxone is a third-generation broad-spectrum cephalosporin with potent activity against Gram-negative bacteria. Sulbactam is a β-lactamase inhibitor that irreversibly inactivates a wide range of β-lactamase enzymes, thereby protecting ceftriaxone from degradation and extending its spectrum to include many β-lactamase-producing organisms, including some resistant strains. This combination is particularly valuable in the Indian context for treating serious hospital and community-acquired infections where resistance due to ESBL (Extended-Spectrum Beta-Lactamase) production is a significant concern.
Adult: 1.5 g (Ceftriaxone 1000mg + Sulbactam 500mg) every 12 hours or every 24 hours, depending on severity of infection. For life-threatening infections (e.g., meningitis, septic shock): 1.5 g every 12 hours. Maximum daily dose: Ceftriaxone 4g, Sulbactam 2g.
Note: For IV use: Reconstitute with Water for Injection, 0.9% Sodium Chloride, or 5% Dextrose. Administer as a slow IV injection over 3-5 minutes or as an IV infusion over 30 minutes. For IM use: Reconstitute with Sterile Water for Injection or preferably 1% Lidocaine HCl solution (without epinephrine) to reduce pain. Inject deeply into a large muscle mass (gluteus maximus). DO NOT MIX WITH CALCIUM-CONTAINING SOLUTIONS (e.g., Ringer's Lactate) in the same IV line or administer simultaneously.
Ceftriaxone binds to and inhibits penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This inhibition disrupts the final transpeptidation step of peptidoglycan synthesis in the bacterial cell wall, leading to the formation of a defective cell wall and osmotic lysis of the bacterium. Sulbactam has weak intrinsic antibacterial activity but acts as a competitive, irreversible inhibitor of a wide range of beta-lactamase enzymes (including TEM-1, SHV-1, and some Class A ESBLs). By binding covalently to these enzymes, it prevents them from hydrolyzing and inactivating ceftriaxone, thereby restoring ceftriaxone's activity against beta-lactamase-producing bacteria.
Pregnancy: Pregnancy Category B. Ceftriaxone and sulbactam cross the placenta. Studies in animals have not shown teratogenic effects. Use during pregnancy only if clearly needed, after assessing benefit vs. risk. Generally considered safe for treating serious infections in pregnancy.
Driving: Dizziness has been reported rarely. Patients should be cautioned about driving or operating machinery if they experience dizziness.
| Warfarin and other Oral Anticoagulants | Ceftriaxone may potentiate anticoagulant effect by altering gut flora and reducing vitamin K synthesis, and possibly by displacement from protein binding sites. Increased risk of bleeding. | Major |
| Aminoglycosides (e.g., Gentamicin, Amikacin) | Synergistic antibacterial effect against some organisms (e.g., Pseudomonas). However, increased risk of nephrotoxicity, though ceftriaxone is less nephrotoxic than other cephalosporins. | Moderate |
| Loop Diuretics (e.g., Furosemide) | Increased risk of nephrotoxicity. | Moderate |
| Probenecid | Does NOT significantly affect ceftriaxone excretion (as it is cleared by biliary and renal routes). May decrease renal clearance of sulbactam, potentially increasing its serum levels. | Minor |
| Calcium-containing IV solutions (Ringer's Lactate, Parenteral Nutrition) | Risk of precipitation of ceftriaxone-calcium salts, potentially fatal in neonates. In adults, do not mix or administer simultaneously via the same IV line. A flushing line is required between infusions. | Major |
| Chloramphenicol | Antagonistic in vitro antibacterial effect; avoid concurrent use. | Moderate |
| Ethanol | Disulfiram-like reaction (flushing, tachycardia, nausea) is rare with ceftriaxone but has been reported with some cephalosporins. Caution advised. | Moderate |
Same composition (Ceftriaxone (1000mg) + Sulbactam (500mg)), different brands: